Novel molecular targets for the therapy of castration-resistant prostate cancer

European Urology

Volumn 61, Issue 5, 2012, Pages 950-960

  Agarwal, Neeraj ^a   Sonpavde, Guru ^b,c   Sternberg, Cora N ^d  

^a UNIVERSITY OF UTAH   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Androgen pathway inhibitors; Androgen receptor; Biologic agents; Chemotherapy; Immunotherapy; Molecular targets; Prostate cancer; Skeletal related events

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ABIRATERONE ACETATE; AFLIBERCEPT; AZACITIDINE; BAVITUXIMAB; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CANCER VACCINE; CARBOPLATIN; CUSTIRSEN; DASATINIB; DOCETAXEL; DOVITINIB; EVEROLIMUS; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; MITOXANTRONE; OLARATUMAB; ORTERONEL; PAZOPANIB; PREDNISONE; RETASPIMYCIN; RILOTUMUMAB; TASQUINIMOD; TEMSIROLIMUS; UNINDEXED DRUG; VORINOSTAT;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHROMATIN STRUCTURE; DNA DAMAGE; DNA REPLICATION; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; FATIGUE; GENE MUTATION; GENETIC TRANSCRIPTION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNE RESPONSE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MITOSIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANDROSTADIENES; ANILIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CANCER VACCINES; CARCINOMA; CLINICAL TRIALS, PHASE III AS TOPIC; CLUSTERIN; HUMANS; MALE; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PYRIDINES; PYRIMIDINES; QUINOLINES; RADIUM; RECOMBINANT FUSION PROTEINS; TAXOIDS; THIAZOLES; TISSUE EXTRACTS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84859425018     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.12.028     Document Type: Review

References (71)

1. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
2. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
3. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
4. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
5. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
6. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
7. K.G. Hermans, R. van Marion, H. van Dekken, G. Jenster, W.M. van Weerden, and J. Trapman TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer Cancer Res 66 2006 10658 10663 (Pubitemid 44876959)
8. R. Ummanni, F. Mundt, and H. Pospisil Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform PLoS One 6 2011 e16833
9. T. Kaku, T. Hitaka, and A. Ojida Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer Bioorg Med Chem 19 2011 6383 6399
10. E.A. Mostaghel, B.T. Marck, and S.R. Plymate Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913 5925
11. H.I. Scher, T.M. Beer, and C.S. Higano Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
12. Medivation and Astellas announce positive survival data from interim analysis of phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer [press release]. San Francisco, CA: Medivation and Astellas; November 3, 2011. http://www.astellas.us/docs/us/AFFIRM-IA-Press-Release-11-2-11-final.pdf.
13. R.J. Andersen, N.R. Mawji, and J. Wang Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor Cancer Cell 17 2010 535 546
14. P. Mendiratta, E. Mostaghel, and J. Guinney Genomic strategy for targeting therapy in castration-resistant prostate cancer J Clin Oncol 27 2009 2022 2029
15. L. Chen, S. Meng, and H. Wang Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 Mol Cancer Ther 4 2005 1311 1319
16. D. Bradley, D. Rathkopf, and R. Dunn Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium Cancer 115 2009 5541 5549
17. G. Sonpavde, A.M. Aparicio, and F. Zhan Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer Urologic Oncol 29 2011 682 689
18. A. Hoos, A.M. Eggermont, and S. Janetzki Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 2010 1388 1397
19. D.B. Solit, F.F. Zheng, and M. Drobnjak 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin Cancer Res 8 2002 986 993 (Pubitemid 34517631)
20. W.K. Oh, M.D. Galsky, and W.M. Stadler Multicenter phase II trial of the heat shock protein 90 inhibitor, Retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer Urology 78 2011 626 630
21. G. Sonpavde, J. McMannis, and Y. Bai Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC) [abstract 132] J Clin Oncol 29 Suppl 7 2011
22. J.R. Brahmer, C.G. Drake, and I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
23. A.I. Chin, A.K. Miyahira, and A. Covarrubias Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance Cancer Res 70 2010 2595 2603
24. J.A. Tuxhorn, S.J. McAlhany, F. Yang, T.D. Dang, and D.R. Rowley Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model Cancer Res 62 2002 6021 6025 (Pubitemid 35244446)
25. S.T. Tagawa, H. Beltran, and S. Vallabhajosula Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer Cancer 116 2010 1075 1083
26. W.K. Kelly, S. Halabi, and M.A. Carducci A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 [abstract LBA4511] J Clin Oncol 28 Suppl 2010 18s
27. M.D. Michaelson, S. Oudard, and Y. Ou Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU + P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract 4515] J Clin Oncol 29 Suppl 2011
28. T.S. Udayakumar, E.L. Bair, R.B. Nagle, and G.T. Bowden Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression Mol Carcinog 38 2003 70 77 (Pubitemid 37255142)
29. R. Pili, M. Haggman, and W.M. Stadler Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer J Clin Oncol 29 2011 4022 4028
30. E.Y. Yu, G. Wilding, and E. Posadas Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 2009 7421 7428
31. Y. Dai, and D.W. Siemann BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro Mol Cancer Ther 9 2010 1554 1561
32. M. Verras, J. Lee, H. Xue, T.H. Li, Y. Wang, and Z. Sun The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression Cancer Res 67 2007 967 975
33. M. Hussain, M.R. Smith, and C. Sweeney Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract 4516] J Clin Oncol 29 Suppl 2011
34. L.R. Molife, P.C. Fong, and L. Paccagnella The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study Br J Cancer 103 2010 332 339
35. Higano CS, Alumkal JJ, Ryan CJ, et al. A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): Feasibility of every 3-week dosing and updated results. Abstract 189 presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA. American Society of Clinical Oncology Web site. www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view&confID=73&abstractID=30567.
36. A. Alva, S. Slovin, and S. Daignault Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer. NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium Invest New Drugs 30 2012 749 757
37. B. Bin Hafeez, V.M. Adhami, and M. Asim Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator Clin Cancer Res 15 2009 452 459
38. O. Leshem, S. Madar, and I. Kogan-Sakin TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model PLoS One 6 2011 e21650
39. M. Lauth, A. Bergstrom, T. Shimokawa, and R. Toftgard Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists Proc Natl Acad Sci U S A 104 2007 8455 8460 (Pubitemid 47175509)
40. H. Tanaka, E. Kono, and C.P. Tran Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance Nat Med 16 2010 1414 1420
41. C.N. Papandreou, D.D. Daliani, and D. Nix Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 2004 2108 2121 (Pubitemid 41095144)
42. G. Ayala, J. Yan, and R. Li Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt Clin Cancer Res 14 2008 7511 7518
43. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, and N.J. Maitland Prospective identification of tumorigenic prostate cancer stem cells Cancer Res 65 2005 10946 10951 (Pubitemid 41713363)
44. J. Miki, B. Furusato, and H. Li Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens Cancer Res 67 2007 3153 3161 (Pubitemid 46724852)
45. B.S. Taylor, N. Schultz, and H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
46. A. Carracedo, L. Ma, and J. Teruya-Feldstein Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 2008 3065 3074
47. A. Dubrovska, J. Elliott, and R.J. Salamone Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma Clin Cancer Res 16 2010 5692 5702
48. B.S. Carver, C. Chapinski, and J. Wongvipat Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
49. C.N. Sternberg, H. Dumez, and H. Van Poppel Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer Ann Oncol 20 2009 1264 1269
50. Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. In press. DOI:10.1093/annonc/ mdr555.
51. K.N. Chi, S.J. Hotte, and E.Y. Yu Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 4247 4254
52. Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. In press. DOI:10.1093/annonc/ mdr353.
53. S. Liu, Y. Qi, and Y. Ge Telomerase as an important target of androgen signaling blockade for prostate cancer treatment Mol Cancer Ther 9 2010 2016 2025
54. S.K. Hong, J.H. Kim, M.F. Lin, and J.I. Park The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells Exp Cell Res 317 2011 2671 2682
55. S. Wee, Z. Jagani, and K.X. Xiang PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 69 2009 4286 4293
56. C.M. Canil, M.J. Moore, and E. Winquist Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group J Clin Oncol 23 2005 455 460 (Pubitemid 46224221)
57. A. Ziada, A. Barqawi, and L.M. Glode The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial Prostate 60 2004 332 337 (Pubitemid 39050653)
58. J.C. Brenner, B. Ateeq, and Y. Li Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 19 2011 664 678
59. B. Ateeq, S.A. Tomlins, and B. Laxman Therapeutic targeting of SPINK1-positive prostate cancer Sci Transl Med 3 2011 72ra17
60. M.T. Fleming, G. Sonpavde, and M. Kolodziej Association of rash with outcomes in a randomized Phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone following docetaxel for metastatic castration-resistant prostate cancer Clin Genitourin Cancer 10 2012 6 14
61. H.I. Scher, X. Jia, and K. Chi Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer J Clin Oncol 29 2011 2191 2198
62. G. Sonpavde, T.C. Thompson, and R.K. Jain GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy Clin Cancer Res 17 2011 7174 7182
63. T.M. Beer, C.W. Ryan, and P.M. Venner Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel Cancer 112 2008 326 330
64. R.W. Ross, T.M. Beer, and S. Jacobus A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel Cancer 112 2008 521 526 (Pubitemid 351186193)
65. J.E. Rosenberg, V.K. Weinberg, and W.K. Kelly Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 2007 556 563 (Pubitemid 47106144)
66. de Bono JS, Molife LR, Sonpavde G, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol. In press. DOI:10.1093/annonc/mdr380.
67. Smith MR. Late-breaking plenary session. At: American Urological Association (AUA) Annual Meeting; May 15, 2011; Washington, DC, USA.
68. Parker C. Phase III trial of alpharadin (radium-223) for metastatic castration-resistant prostate cancer with bone metastases. Paper presented at: European Society for Medical Oncology European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden.
69. H.I. Scher, G. Heller, and G.A. Molina Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract LBA4517] J Clin Oncol 29 Suppl 2011
70. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
71. S. Bamford, E. Dawson, and S. Forbes The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website Br J Cancer 91 2004 355 358 (Pubitemid 39037083)